Statement of Principles concerning Meniere disease and Meniere syndrome (Reasonable Hypothesis) (No. 68 of 2024)

This instrument is a Statement of Principles (SoP) issued by the Repatriation Medical Authority under subsection 196B(2) of the Veterans' Entitlements Act 1986 (the VEA) that sets the medical criteria for when a reasonable hypothesis exists connecting Meniere disease and Meniere syndrome (and death from them) to a person’s relevant service (s3, s7, s8). The document replaces the prior SoP for Meniere’s disease made in 2015 (s4). It commences on 24 September 2024 (s2) and is expressly made to apply to claims that fall under section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) (s5).

Mechanically, the instrument does three things. First, it defines the clinical scope of the conditions covered: separate statutory definitions for “Meniere disease” (primary/idiopathic bilateral cochleo‑vestibular pathology on the same side with episodic vertigo, sensorineural hearing loss and/or tinnitus) and “Meniere syndrome” (secondary pathology with similar clinical manifestations) (s7(2)-(3)). Both expressly exclude vestibular migraine (s7(2)(c), s7(3)(c)). Second, it sets the threshold for a reasonable hypothesis: at least one enumerated factor listed in section 9 must exist in the person (s9). Those factors are discrete clinical events, comorbid diseases, prior exposures (drug or surgery), or access to care problems (s9(1)-(7)). Third, it imposes a service nexus requirement: any listed factor must be related to the person’s relevant service as defined in the Schedule (s10(1)), and the clinical‑worsening elements of the factors are limited by the condition that the Meniere disease/syndrome must have been suffered or contracted before or during (but not arising out of) service (s10(2)).

The SoP also clarifies coding: while ICD‑10‑AM code H81.0 corresponds to Meniere disease/syndrome, the statutory meaning is the text of subsections 7(2) and 7(3), not the code alone (s7(4)-(5)). Death from Meniere disease/syndrome is included where a terminal event or condition was contributed to by the condition; “terminal event” is defined in the Schedule (s7(6); Schedule definition). Finally, the SoP cross‑references other SoPs: if a listed factor refers to an injury or disease covered by another SoP, that other SoP’s factors apply as in force (s11). The instrument therefore operates as a medical‑evidentiary benchmark that decision‑makers will apply when assessing entitlement under the cited provisions of the VEA and MRCA (s3, s5).

The central legal and medical concepts in the SoP are: the statutory authority to issue SoPs, the definitional limits on the covered conditions, the enumerated causal factors that will suffice to raise a reasonable hypothesis, the temporal and service‑nexus constraints, and the cross‑reference to other SoPs.

Authority and scope: The Repatriation Medical Authority makes this instrument under s196B(2) of the VEA (s3). The instrument explicitly applies to claims governed by s120A of the VEA or s338 of the MRCA (s5). Those references locate the instrument within the statutory adjudication framework for veterans’ entitlements; the SoP supplies the medical link that adjudicators will use to test whether a reasonable hypothesis exists.

Definitions of the conditions: The SoP draws a clinical distinction between Meniere disease and Meniere syndrome. Meniere disease is defined as primary (idiopathic) pathology involving both cochlea and vestibular apparatus on the same side, with episodic attacks of vertigo, sensorineural hearing loss and/or tinnitus, and includes primary endolymphatic hydrops (s7(2)(a)-(b)). Meniere syndrome is defined as secondary pathology permanently affecting those structures or the vestibulocochlear nerve on the same side, with the same clinical manifestations and including secondary endolymphatic hydrops (s7(3)(a)-(b)). Both expressly exclude vestibular migraine (s7(2)(c), s7(3)(c)). The SoP notes that progressive inter‑episodic hearing loss is a component of Meniere disease (Note after s7(2)) and that bilateral disease may invoke the SoP twice (Note after s7(2) and after s7(3)).

Reasonable hypothesis factors: Section 9 lists the discrete factors, any one of which must be present to raise the reasonable hypothesis. They are:

• moderate to severe traumatic brain injury (TBI) within 6 months before clinical onset or clinical worsening (s9(1));
• otosyphilis of the affected ear at the time of clinical onset (s9(2));
• specified autoimmune diseases (a list of eight named diseases) occurring before clinical onset (s9(3)(a)-(h));
• middle ear or inner ear surgery at least 2 months before clinical onset (s9(4));
• taking hydroxychloroquine in the 5 months before clinical onset (s9(5));
• taking the aminoglycoside antibiotics amikacin, gentamicin or tobramycin before clinical onset (s9(6]);
• inability to obtain appropriate clinical management for Meniere disease and syndrome before clinical worsening (s9(7]).

Temporal and nexus constraints: Section 10 requires each factor to be related to the person’s relevant service (s10(1)). Section 10(2) limits the clinical‑worsening aspects of the listed factors to situations where the Meniere disease/syndrome was suffered or contracted before or during, but did not arise out of, the relevant service , i.e. it is framed as material contribution or aggravation rather than as a cause arising from service.

Primary affected persons: The instrument applies to claimants whose entitlement claims fall under section 120A of the VEA or section 338 of the MRCA (s5). Those are the legal pathways for veterans’ claims where the reasonable‑hypothesis test is engaged; therefore current and former members of the Forces, members of Peacekeeping Forces, and veterans who render the types of “relevant service” listed in the Schedule are the class from which affected claimants will come (Schedule, Definitions: relevant service).

Decision‑makers and administrative actors: The Repatriation Medical Authority is the author of the SoP (s3). The instrument will be applied by the decision‑makers who adjudicate VEA and MRCA claims: the instrument itself states it applies to claims under the cited provisions, which places it in the statutory framework used by those adjudicators (s5). Although the instrument does not name the administrative office or decision body, its function is to provide medical criteria used when adjudicating entitlements.

Medical practitioners and record keepers: Clinicians, hospitals and allied health providers who diagnose or treat Meniere disease/syndrome, perform middle/inner ear surgery, treat TBIs, manage autoimmune disease, or prescribe the listed drugs will be affected in practice because the SoP’s listed factors are time‑sensitive and diagnosis‑sensitive (s9(1)-(6)). Clinical records, diagnostic tests and precise dates will be the primary evidentiary basis for showing a factor exists within the time windows specified (for example TBI within six months, surgery at least two months before onset, hydroxychloroquine within five months) (s9(1), s9(4)-(5)). The vague factor “inability to obtain appropriate clinical management” (s9(7)) will also require documentation of attempts to obtain care.

Other statutes and SoPs: The instrument explicitly interacts with other SoPs if a listed factor is itself an injury or disease covered by another SoP (s11). That means that owners of claims involving multiple conditions must be aware of the other SoPs in force and their terms.

Who benefits and how: Claimants who can show at least one of the enumerated factors, and that the factor is related to their relevant service, will have a statutory benchmark for establishing a reasonable hypothesis linking their Meniere disease/syndrome (or death from it) to service (s9, s10(1)). The SoP therefore concentrates legal benefit on those claimants with evidence matching the listed factors and the required service nexus.

Who bears administrative burden: Collating medical records, obtaining expert opinions, demonstrating timing of exposures and relating those to relevant service will fall on claimants and their advisers. Decision‑makers will need to apply the SoP’s precise language when evaluating whether the reasonable hypothesis threshold has been met. The instrument itself imposes no monetary charge, criminal penalty or licensing requirement; its operational cost is administrative and evidentiary (s3-s11, Schedule).

This instrument is not a statute establishing new criminal offences or civil obligations, but it creates binding medical criteria for statutory decision‑making. The core duties and rights are internal to the entitlement framework created by the VEA and the MRCA and are implemented through the SoP.

Duty to apply the SoP when relevant: The instrument is made under the authority of subsection 196B(2) of the VEA and applies to claims to which s120A VEA or s338 MRCA apply (s3, s5). The duty to apply this SoP arises for adjudicators assessing whether a reasonable hypothesis exists for Meniere disease/syndrome in the context of those claims. The SoP therefore prescribes the evidentiary rules that decision‑makers must use to determine if the statutory reasonable‑hypothesis test is met.

Duty to show a factor and nexus: For a claimant, the operative burden to raise a reasonable hypothesis under this SoP is to demonstrate the existence of at least one of the factors listed in section 9 and to show that the factor is related to the person’s relevant service (s9; s10(1)). The SoP treats the listed factors as determinative triggers for a reasonable hypothesis, subject to relation to service.

Limited scope for aggravation claims: Section 10(2) imposes an operational constraint for clinical‑worsening claims: the clinical‑worsening elements of the factors in section 9 apply only where the Meniere condition was suffered or contracted before or during, but did not arise out of, the relevant service. In other words, the SoP contemplates material contribution to or aggravation of pre‑existing conditions by service, rather than establishing that the disease arose out of service in the first instance when the disease itself first occurred during service.

Right to rely on other SoPs: Section 11 provides that if a factor in section 9 relates to an injury or disease that is covered by another SoP, then the factors in that other SoP apply according to its terms as in force from time to time. That gives claimants the procedural right to have the separate SoP’s criteria applied where relevant.

Evidence expectations: The SoP lists temporal and diagnostic criteria (for example, TBI within six months of onset, surgery at least two months before onset, hydroxychloroquine within five months) which create de facto evidentiary standards for the existence of a factor (s9(1), s9(4)-(5)). Clinicians, claimants and advisers will be expected to document dates, diagnoses and treatment courses to satisfy those criteria. For death claims, the SoP requires that death be from a terminal event or condition contributed to by the Meniere disease/syndrome, with “terminal event” defined in the Schedule (s7(6); Schedule definition).

The instrument contains no express penalties, enforcement fines, or criminal provisions. It is a determinative medical standard used in entitlement adjudication, not a standalone penal measure (s3-s11). Consequently, enforcement is indirect and administrative: the SoP is enforced in practice through claims decisions under the VEA and MRCA that accept or reject entitlement based on whether a reasonable hypothesis is raised.

Administrative application and effect on decisions: The SoP’s provisions will be applied by decision‑makers when assessing claims to which section 120A of the VEA or section 338 of the MRCA apply (s3, s5). If a claimant establishes at least one of the factors in section 9 and relates it to their relevant service as required by section 10(1), a reasonable hypothesis will be raised. That finding will influence whether the claimant proceeds to a merits assessment under the VEA/MRCA regime. Conversely, absence of an enumerated factor (or failure to link it to relevant service) will provide grounds for the decision‑maker to reject a reasonable‑hypothesis claim. The SoP therefore functions as a binary threshold in adjudicative practice.

Evidentiary enforcement: Because the listed factors include time‑limited elements (for example TBI within six months, hydroxychloroquine within five months, surgery at least two months before onset), enforcement is effected by evidentiary assessments of clinical records, prescriptions, surgical reports and contemporaneous documentation (s9(1), s9(4)-(5)). The instrument thereby imports an evidentiary burden: claimants must produce clinical proof and dates; adjudicators must assess those records against the SoP language.

No criminal sanction for false statements in the instrument: The SoP does not itself create offences for false statements or fraudulent claims. Any penalties for false claims would be those available under the VEA or MRCA or other laws, but such penalties are not specified within this instrument. The document is silent on sanctioning mechanisms.

Potential administrative consequences: The practical enforcement mechanism is denial of entitlement where the SoP is not satisfied. Denial can trigger internal review, appeals or other administrative remedies under the VEA or MRCA appeal processes (not set out in this instrument). Those remedial processes are part of the broader statutory framework but are not described or altered by this SoP.

Discretion and interpretive enforcement risks: The SoP uses terms that may require clinical interpretation , for example “moderate to severe traumatic brain injury,” “inability to obtain appropriate clinical management,” and “clinical onset or clinical worsening” (s9(1), s9(7), s9 generally). That leaves room for adjudicative discretion in evaluating the sufficiency of evidence. The instrument’s cross‑reference rule (s11) can also import interpretive variation depending on the content of other SoPs.

The SoP is an instrument made under the VEA and designed to operate within the existing VEA and MRCA entitlement frameworks. Its interaction with other laws and instruments is regulated explicitly in several provisions.

Statutory source and application: The instrument is made under subsection 196B(2) of the VEA (s3). It applies to claims falling under s120A of the VEA or s338 of the MRCA (s5). Thus, it is incorporated into the adjudicative machinery of those Acts; adjudicators applying the VEA/MRCA reasonable‑hypothesis tests will use the SoP as the medical yardstick.

Relationship with other Statements of Principles: Section 11 provides a direct mechanism for interaction with other SoPs. If a factor in section 9 refers to an injury or disease that itself is covered by another SoP, then the factors in that other SoP apply “in accordance with the terms of that Statement of Principles as in force from time to time” (s11). That cross‑reference creates a layered statutory interaction: where factors overlap with other named conditions, the other SoP’s criteria become part of the legal analysis. This can produce chains of dependence between SoPs and may require decision‑makers to consult multiple SoPs.

ICD‑10‑AM coding: The instrument notes that although Meniere disease and Meniere syndrome attract ICD‑10‑AM code H81.0, the statutory meaning for the SoP is the textual definitions in subsections 7(2) and 7(3) (s7(4)-(5)). Therefore, while coding may be used as supporting evidence, the legal test is the statutory language, not the code alone. The ICD reference is to the version effective 1 July 2017 (s7(5)). That creates an interaction between diagnostic coding systems and statutory definitions: codes can assist but not supplant the SoP text.

Service definitions and other Acts: The Schedule defines “relevant service” by reference to particular forms of service under the VEA (operational, peacekeeping, hazardous, British nuclear test defence) and the MRCA (warlike and non‑warlike) (Schedule, Definitions). That embeds statutory cross‑references to those Acts in the operation of the SoP and limits its application to the particular legal categories of service established by the VEA and MRCA. Claims that do not meet the Schedule’s definition of relevant service will fall outside the SoP’s scope.

Death and terminal events: The SoP includes death from Meniere disease and Meniere syndrome when the disease contributed to a terminal event or condition; the Schedule defines “terminal event” with examples such as pneumonia and respiratory failure (s7(6); Schedule). This links the SoP to statutory death benefits and the death assessment processes under the VEA/MRCA framework.

This instrument replaces the prior Statement of Principles concerning Meniere's disease No. 108 of 2015 (Federal Register of Legislation No. F2015L01328), which is expressly repealed by section 4. The instrument itself is dated 20 August 2024 and has a commencement date of 24 September 2024 (s4; s2). Those are the only express historical or amendment details contained in the text.

What the instrument changes mechanically: The repeal clause (s4) removes the 2015 SoP from operation and substitutes the 2024 Statement of Principles for use in claims. The immediate legal effect is that from 24 September 2024 the 2015 instrument is no longer in force and adjudicators must apply the 2024 criteria in its place (s2, s4). The instrument does not include a transitional provision expressly addressing claims made or proceedings commenced before commencement; the absence of transitional language means that, operationally, decision‑makers will apply the new SoP to claims that are subject to s120A VEA or s338 MRCA from the commencement date onwards (s2, s5). The text does not elaborate on grandfathering or transitional evidentiary rules.

No further amendment history within the instrument: The instrument contains no schedule of prior amendments to this edition (it is presented as No. 68 of 2024) and provides no mechanism for amendment beyond the general power in the VEA under which SoPs are issued (s3). Any future amendments would likely be made under the same statutory power and would themselves need to be published and given a commencement date.

Implication for advisers and litigators: The repeal of the 2015 SoP is a material legal change. Lawyers and advocates acting on claims straddling the date of commencement should check the administrative practices of decision‑makers for any guidance on how pre‑commencement evidence is to be treated in light of a new SoP. The instrument itself provides no transitional direction; the statutory framework for appeals and review under the VEA and MRCA will determine procedural consequences for claims lodged or decided across the change‑over.

Record‑keeping implication: Clinicians and claimants should note the commencement date because evidentiary assessments made after 24 September 2024 will be judged against the 2024 criteria, including the enumerated factors and the precise temporal limits they impose (s9). The repealed 2015 SoP is no longer the governing instrument for new decisions from the commencement date (s2, s4).

The instrument contains no reference to any judicial decisions, litigation history, case law or precedents. It does not cite or summarise any court decisions, nor does it identify prior legal challenges to the 2015 SoP or to the RMA’s determinations more generally. The only legal references in the text are to statutory provisions (s3 quoting subsection 196B(2) of the VEA), other SoPs (s11), and diagnostic codes (s7(4)-(5)).

Consequences of the absence of litigation history in the text: Because the SoP itself makes no statement about litigation, there is no source‑grounded judicial interpretation to rely upon within this instrument. Practitioners must therefore interpret the instrument’s terms as written and, where useful, look beyond this instrument to relevant judicial authorities, administrative determinations and the statutory text of the VEA and MRCA for guidance on evidentiary standards, review pathways and the standard of proof. The instrument does not provide that additional context.

Areas likely to generate litigation or review (from the instrument’s content): Although the instrument contains no litigation history, its content indicates several points that may be the focus of procedural or substantive disputes in decision‑making and appeals:

• Interpretation of temporal phrases such as “within the 6 months before clinical onset or clinical worsening” (s9(1)), “at least 2 months before clinical onset” (s9(4)), and “in the 5 months before clinical onset” (s9(5)). Disputes may arise about how onset and worsening are dated.
• The scope and meaning of graded clinical terms like “moderate to severe traumatic brain injury” and “inability to obtain appropriate clinical management” (s9(1), s9(7)). These concepts will require medical evidence and may be contested.
• The application of s10(2) to clinical‑worsening claims: whether a disease that was suffered or contracted before or during service but did not arise out of service was materially contributed to or aggravated by service.
• The effect of cross‑referencing other SoPs under s11; disagreements may surface where factors point to conditions governed by different SoPs with different criteria.

No litigated interpretation available in this instrument: Because the SoP does not provide judicial guidance, litigators and advisers will need to build arguments from the statutory wording and supporting medical material when advancing or defending claims. Decision‑makers’ prior administrative practice (not contained in this instrument) and the underlying statutory framework in the VEA and MRCA will be the channels through which litigated interpretations develop.

The instrument contains several drafting choices and substantive limits that create potential pitfalls for claimants, clinicians and advisers. These are practical hazards that flow from the language of the SoP itself.

1. Narrow, specific temporal windows

• TBI: Section 9(1) requires a “moderate to severe traumatic brain injury within the 6 months before clinical onset or clinical worsening.” The six‑month window is explicit; TBIs outside that window do not meet this factor. Precise dating of TBI and onset is therefore critical (s9(1)).
• Surgery: Section 9(4) requires middle ear or inner ear surgery “at least 2 months before clinical onset.” The minimum interval is stated; surgery more proximate than two months will not satisfy this factor (s9(4)).
• Hydroxychloroquine: Section 9(5) specifies taking hydroxychloroquine “in the 5 months before clinical onset.” Again, this is a limited exposure window (s9(5)).
• Aminoglycosides: By contrast, section 9(6) simply requires “taking amikacin, gentamicin, or tobramycin before clinical onset,” with no explicit temporal limit. That inconsistency between factors can cause evidentiary ambiguity (s9(6)).

2. Diagnostic exclusions and coding caveats

• Vestibular migraine is explicitly excluded for both Meniere disease and Meniere syndrome (s7(2)(c), s7(3)(c)). A claimant with an alternative diagnosis of vestibular migraine cannot rely on this SoP.
• Although ICD‑10‑AM code H81.0 relates to these conditions, the statutory meaning is the text in subsections 7(2) and 7(3), not the code per se (s7(4)-(5)). Reliance on coding without matching the statutory clinical description is insufficient.

3. “Inability to obtain appropriate clinical management” is vague

• The final factor in section 9(7) is imprecise: it requires inability to obtain appropriate clinical management for Meniere disease before clinical worsening. The SoP provides no guidance on what constitutes “appropriate clinical management,” or how to evidence inability to obtain it. That vagueness increases the risk of dispute over causation and admissibility (s9(7)).

4. Service nexus constraint and aggravation limitation

• Every factor must be related to the person’s relevant service (s10(1)). Showing that a listed factor occurred does not suffice if it cannot be related to the specified categories of “relevant service” in the Schedule.

Compliance here means assembling the evidence and legal arguments necessary to raise a reasonable hypothesis under the SoP and to convince a decision‑maker applying the VEA or MRCA that a service nexus exists. The following practical checklist and steps track the instrument’s language and evidentiary implications.

1. Confirm statutory pathway and scope

• Verify that the claim is one to which section 120A of the VEA or section 338 of the MRCA applies (s5). If not, this SoP does not govern the reasonable‑hypothesis assessment.

2. Match diagnosis to statutory definitions

• Ensure the claimant’s diagnosis fits the statutory descriptions in subsections 7(2) or 7(3). For Meniere disease, establish primary (idiopathic) involvement of cochlea and vestibular apparatus on the same side with episodic vertigo and sensorineural hearing loss and/or tinnitus (s7(2)(a)). For Meniere syndrome, establish secondary and permanent involvement (s7(3)(a)). Explicitly exclude vestibular migraine if present (s7(2)(c), s7(3)(c)).
• Note that ICD‑10‑AM coding (H81.0) may assist but is not determinative; ensure the narrative medical evidence aligns to the subsections (s7(4)-(5)).

3. Identify and document at least one enumerated factor (section 9)

• For each potential factor, obtain primary records, with dates:
  • TBI: hospital records describing the TBI and grading to show “moderate to severe,” and the date. Provide contemporaneous neurosurgical/neurology notes showing timing in relation to clinical onset or worsening; ensure the TBI is within six months prior to onset/worsening (s9(1)).
  • Otosyphilis: serology and ENT/specialist records confirming otosyphilis in the affected ear at time of clinical onset (s9(2)).
  • Autoimmune diseases: diagnostic records for any listed disease (e.g. rheumatoid arthritis, systemic lupus erythematosus, Hashimoto thyroiditis, etc.) showing diagnosis before clinical onset of Meniere manifestations (s9(3)(a)-(h)).
  • Ear surgery: operative reports and discharge summaries showing middle ear or inner ear surgery at least two months before clinical onset (s9(4)).
  • Hydroxychloroquine: prescribing records and pharmacy dispensing showing hydroxychloroquine use in the five months before clinical onset (s9(5)).
  • Aminoglycosides: prescription, administration or hospital records showing amikacin, gentamicin or tobramycin use before clinical onset (s9(6)).